The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Long-term outcomes in patients with muscle-invasive bladder cancer after bladder-preserving combined-modality therapy: A pooled analysis of RTOG 8802, 8903, 9506, 9706, 9906, and 0233.
Raymond H. Mak
No relevant relationships to disclose
Daniel Hunt
No relevant relationships to disclose
William U. Shipley
Stock Ownership - Pfizer
Jason Alexander Efstathiou
No relevant relationships to disclose
William J. Tester
No relevant relationships to disclose
Michael P. Hagan
No relevant relationships to disclose
Donald S. Kaufman
No relevant relationships to disclose
Niall M. Heney
No relevant relationships to disclose
Anthony L. Zietman
No relevant relationships to disclose